CoChat

Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy

Open access

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index; 68 of the 168 sources its claims cite were checked for support.

Abstract

Oncogenesis is associated with intestinal dysbiosis, and stool shotgun metagenomic sequencing in individuals with this condition might constitute a non-invasive approach for the early diagnosis of several cancer types. The prognostic relevance of antibiotic intake and gut microbiota composition urged investigators to develop tools for the detection of intestinal dysbiosis to enable patient stratification and microbiota-centred clinical interventions. Moreover, since the advent of immune-checkpoint inhibitors (ICIs) in oncology, the identification of biomarkers for predicting their efficacy before starting treatment has been an unmet medical need. Many previous studies addressing this question, including a meta-analysis described herein, have led to the description of Gut OncoMicrobiome Signatures (GOMS). In this Review, we discuss how patients with cancer across various subtypes share several GOMS with individuals with seemingly unrelated chronic inflammatory disorders who, in turn, tend to have GOMS different from those of healthy individuals. We discuss findings from the aforementioned meta-analysis of GOMS patterns associated with clinical benefit from or resistance to ICIs across different cancer types (in 808 patients), with a focus on metabolic and immunological surrogate markers of intestinal dysbiosis, and propose practical guidelines to incorporate GOMS in decision-making for prospective clinical trials in immuno-oncology.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00785-8

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

33 Valid · 0 Not valid · 70 Not checked · 15 Own results and interpretations

54 more claims · 10 with their cited sources checked

Create a free account to see all 118 claims and to verify the 100 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

1 retracted

Show all 221 references

Cited by

See all 150

Metadata

Authors
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L.
Affiliations
  • University of Trento (IT)
  • Inserm (FR)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Zitvogel, Laurence
Venue
Nature Reviews Clinical Oncology
Published
2023-06-26
Volume
20
Issue
9
Pages
583-603
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4382020994
Cited by
141
References
220
Citations by year
2026: 33 · 2025: 50 · 2024: 46 · 2023: 12
FWCI
3.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Iris (University of Trento) (submittedVersion, other-oa)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • American Association for Cancer Research (SU2C-AACR-IRG-19-17)
  • Bristol-Myers Squibb
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Melanoma Research Alliance (4022024)
  • Gilead Sciences
  • Exelixis
  • Seerave Foundation
  • European Commission (716575, 964590, 101095604, 825410, 101045015, HORIZON2020, 818368, H2020)
  • Agence Nationale de la Recherche (ANR-19-CE15-0029, ANR-21-RHUS-0017)
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation pour la Recherche Médicale
  • Fondation ARC pour la Recherche sur le Cancer
  • Ligue Contre le Cancer
  • Institut Universitaire de France
  • Institut National Du Cancer
  • PharmaMar
  • National Institutes of Health (1u01ca230551-01a1, H2020, 1U01CA230551)
  • Genentech
  • University of Texas MD Anderson Cancer Center
  • Stand Up To Cancer (SU2C-AACR-IRG-19-17)
  • Horizon 2020 Framework Programme (OncoBiome 825410, 818368, 964590, 825410)
  • HORIZON EUROPE Framework Programme (818368)
  • Canadian Institutes of Health Research
  • Fonds de Recherche du Québec - Santé
  • Labex Immuno-Oncology
  • National Cancer Institute (R01CA219896, 1U01CA230551, U01 CA230551, R01CA230551)
  • Daiichi Sankyo Europe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
gut microbiota, gut dysbiosis, cancer immunotherapy, immune checkpoint inhibitors, predictive biomarkers, immune checkpoint inhibitor response, immune checkpoint inhibitor resistance, chronic inflammatory diseases, stool metagenomics, patient stratification
MeSH terms
Humans, Immunotherapy, Neoplasms, Prospective Studies, Biomarkers, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41571-023-00785-8
The paper
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023). Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00785-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.